Intratumoral immunotherapy: using the tumor as the remedy
Open Access
- 15 December 2017
- journal article
- review article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 28 (suppl_12), xii33-xii43
- https://doi.org/10.1093/annonc/mdx683
Abstract
Immune checkpoint-targeted monoclonal antibodies directed at Programmed Death Receptor 1 (PD-1), Programmed Death Ligand 1 (PD-L1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) are currently revolutionizing the prognosis of many cancers. By blocking co-inhibitory receptors expressed by antitumor T cells, these antibodies can break the immune tolerance against tumor cells and allow the generation of durable cancer immunity. Benefits in overall survival over conventional therapies have been demonstrated for patients treated with these immunotherapies, leading to multiple approvals of such therapies by regulatory authorities. However, only a minority of patients develop an objective tumor response with long-term survival benefits. Moreover, the systemic delivery of immunotherapies can be responsible for severe auto-immune toxicities. This risk increases dramatically with anti-PD(L)1 and anti-CTLA-4 combinations and currently hampers the development of triple combination immunotherapies. In addition, the price of these novel treatments is probably too high to be reimbursed by health insurances for all the potential indications where immunotherapy has shown activity (i.e. in more than 30 different cancer types). Intratumoral immunotherapy is a therapeutic strategy which aims to use the tumor as its own vaccine. Upon direct injections into the tumor, a high concentration of immunostimulatory products can be achieved in situ, while using small amounts of drugs. Local delivery of immunotherapies allows multiple combination therapies, while preventing significant systemic exposure and off-target toxicities. Despite being uncertain of the dominant epitopes of a given cancer, one can therefore trigger an immune response against the relevant neo-antigens or tumor-associated antigens without the need for their characterization. Such immune stimulation can induce a strong priming of the cancer immunity locally while generating systemic (abscopal) tumor responses, thanks to the circulation of properly activated antitumor immune cells. While addressing many of the current limitations of cancer immunotherapy development, intratumoral immunotherapy also offers a unique opportunity to better understand the dynamics of cancer immunity by allowing sequential and multifocal biopsies at every tumor injection.Keywords
This publication has 59 references indexed in Scilit:
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaNew England Journal of Medicine, 2012
- Immunomodulation by Imiquimod in Patients with High-Risk Primary MelanomaJournal of Investigative Dermatology, 2012
- The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon–Dependent Innate and Adaptive ImmunityCancer Research, 2011
- The patterns and dynamics of genomic instability in metastatic pancreatic cancerNature, 2010
- Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II studyNeuro-Oncology, 2010
- Generation of CD8+ T cell–mediated immunity against idiotype-negative lymphoma escapeesBlood, 2009
- Systemic effects of local radiotherapyThe Lancet Oncology, 2009
- Radiation-induced bystander signalling in cancer therapyNature Reviews Cancer, 2009
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyThe Journal of Experimental Medicine, 2006